135 related articles for article (PubMed ID: 11135216)
1. Circulating soluble Fas ligand in patients with gastric carcinoma.
Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
[TBL] [Abstract][Full Text] [Related]
2. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
3. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
[TBL] [Abstract][Full Text] [Related]
5. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
8. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
Boroumand-Noughabi S; Sima HR; Ghaffarzadehgan K; Jafarzadeh M; Raziee HR; Hosseinnezhad H; Moaven O; Rajabi-Mashhadi MT; Azarian AA; Mashhadinejad M; Tavakkol-Afshari J
BMC Cancer; 2010 Jun; 10():275. PubMed ID: 20534173
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas ligand and atherosclerosis in hypertensive patients.
Okura T; Watanabe S; Jiang Y; Nakamura M; Takata Y; Yang ZH; Kohara K; Kitami Y; Hiwada K
J Hypertens; 2002 May; 20(5):895-8. PubMed ID: 12011650
[TBL] [Abstract][Full Text] [Related]
11. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
[TBL] [Abstract][Full Text] [Related]
13. Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.
Saito H; Takaya S; Osaki T; Ikeguchi M
Gastric Cancer; 2013 Oct; 16(4):473-9. PubMed ID: 23179366
[TBL] [Abstract][Full Text] [Related]
14. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis.
Shiota G; Oyama K; Noguchi N; Takano Y; Kitaoka S; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):3-12. PubMed ID: 9755839
[TBL] [Abstract][Full Text] [Related]
18. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
20. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
